U.S., Jan. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07322718) titled 'Safety and Efficacy Study of RXIM002 in Severe, Relapsed or Refractory Autoimmune Diseases' on Dec. 07, 2025.
Brief Summary: This Phase 1, open-label study evaluates the safety, tolerability, and preliminary efficacy of RXIM002, a CD19-targeting circular RNA-mediated in-vivo CAR T-cell therapy, in adults with severe, relapsed, or refractory B cell-mediated autoimmune diseases.
Study Start Date: Dec. 20, 2025
Study Type: INTERVENTIONAL
Condition:
Relapsed/Refractory B Cell-Mediated Autoimmune Diseases
Intervention:
BIOLOGICAL: RXIM002 product
Prior to infusion of the RXIM002 product, subjects will receive pre-medication if need...